Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L04 IMMUNOSUPPRESSANTS
L04A IMMUNOSUPPRESSANTS
L04AX Other immunosuppressants
L04AX04 Lenalidomide
D09813 Lenalidomide hydrate (JAN) <JP>
USP drug classification [BR:br08302]
Antineoplastics
Immunomodulatory Agents
Imides
Lenalidomide
D09813 Lenalidomide hydrate (JAN)
Therapeutic category of drugs in Japan [BR:br08301]
4 Agents affecting cellular function
42 Antineoplastics
429 Miscellaneous
4291 Other Antitumors
D09813 Lenalidomide hydrate (JAN)
Drug groups [BR:br08330]
Anti-inflammatory
DG01985 Disease modifying anti-rheumatic drug (DMARD)
DG01936 TNF inhibitor
DG00744 Lenalidomide
D09813 Lenalidomide hydrate
Drug classes [BR:br08332]
Immunological agent
DG01936 TNF inhibitor
D09813 Lenalidomide hydrate
Antirheumatic agent
DG01985 Disease modifying anti-rheumatic drug (DMARD)
D09813 Lenalidomide hydrate
Target-based classification of drugs [BR:br08310]
Cytokines and receptors
Cytokines
Tumor necrosis factors
TNF (TNFA, TNFSF2)
D09813 Lenalidomide hydrate (JAN) <JP>
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D09813
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D09813
Drug groups [BR:br08330]
Anti-inflammatory
DG01985 Disease modifying anti-rheumatic drug (DMARD)
DG01936 TNF inhibitor
DG00744 Lenalidomide